Nuclear Medicine Department, Galliera Hospital, Genoa, Italy.
Clinical Trial Unit, Office of the Scientific Director, Galliera Hospital, Genoa, Italy.
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1218-1223. doi: 10.1007/s00259-018-3955-x. Epub 2018 Feb 19.
Current guidelines recommend thyroid hormone withdrawal (THW) of 3-4 weeks before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We aimed to evaluate (1) the reliability of a shorter THW (i.e., 14 days) to achieve adequate TSH levels (i.e., 30 mU/l), (2) the association between length of THW and response to therapy, and (3) the potential association between pre-ablation TSH levels and patients' outcome.
After thyroidectomy, all patients started LT4 therapy, which was subsequently discontinued in order to perform RRA. Patients were broken down into two groups according to the length of THW: group A, 2 weeks of THW, and group B, 3-4 weeks of THW. We used clinical, biochemical, and imaging data to evaluate patients' outcome. By means of univariate and multivariate analysis, including main DTC prognostic factors, we assessed the impact of THW length and TSH levels on patients' outcome.
We evaluated 222 patients, 85 of whom were treated with RRA after a THW period of 2 weeks (group A). All other 137 patients underwent RRA after 3-4 weeks THW (group B). At the time of RRA all patients presented TSH levels ≥30 mU/l. After a median follow-up time of 3.4 years, we found 183 patients (82%) with excellent response to treatment and 39 patients (18%) showing incomplete response. Kaplan-Meier response to therapy curves showed that ablation-Tg, tumor size, and lymph node status were significantly associated with prognosis; no associations were found between THW length, TSH levels, and prognosis. Multivariate Cox model showed that only ablation-Tg was significantly associated with treatment response.
Prior to RRA, a short 2-week THW is an effective method to stimulate TSH levels. No difference in terms of incomplete response to treatment was observed between DTC patients prepared for RRA with a short THW and those with the long THW.
目前的指南建议分化型甲状腺癌(DTC)患者在行放射性碘残留消融(RRA)前进行 3-4 周的甲状腺激素停药(THW)。我们旨在评估(1)较短的 THW(即 14 天)是否能可靠地达到足够的 TSH 水平(即 30mU/L),(2)THW 时间的长短与治疗反应之间的关系,以及(3)消融前 TSH 水平与患者预后之间的潜在关系。
甲状腺切除术后,所有患者开始服用 LT4 治疗,随后停用 LT4 以进行 RRA。根据 THW 的长短,患者被分为两组:A 组,2 周 THW;B 组,3-4 周 THW。我们使用临床、生化和影像学数据来评估患者的预后。通过单因素和多因素分析,包括主要的 DTC 预后因素,我们评估了 THW 时间和 TSH 水平对患者预后的影响。
我们评估了 222 例患者,其中 85 例在 2 周 THW 后接受 RRA(A 组)。其余 137 例患者在 3-4 周 THW 后接受 RRA(B 组)。在 RRA 时,所有患者的 TSH 水平均≥30mU/L。中位随访 3.4 年后,我们发现 183 例(82%)患者治疗反应良好,39 例(18%)患者反应不完全。治疗反应的 Kaplan-Meier 曲线显示,消融-Tg、肿瘤大小和淋巴结状态与预后显著相关;THW 时间、TSH 水平与预后无显著相关性。多因素 Cox 模型显示,只有消融-Tg 与治疗反应显著相关。
在 RRA 之前,2 周的短 THW 是刺激 TSH 水平的有效方法。在为 RRA 准备的 DTC 患者中,与长 THW 相比,采用短 THW 治疗的患者治疗反应不完全的差异无统计学意义。